Why Invest?
- FDA approved biologic for the treatment of cutaneous T-cell lymphoma
- Diversified pipeline of potential first-in-class products with multiple near-term staged catalysts
- Attractive multi-billion-dollar opportunities in adjunctive cancer care, infectious disease and gastrointestinal disease
- Strong research partnerships to advance the pipeline
- Robust balance sheet to support pipeline development and invest in long-term growth
- Seasoned leadership with successful execution-focused track record
Citius is guided by three principles in our mission to deliver best-in-class therapies for patients with critical unmet needs.
- Advance therapies with unique commercial advantages
- Invest in assets with differentiated upside potential
- Create long-term sustainable value for shareholders